Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma
NCT07614035 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2026-05-29
Summary
Bispecific antibodies have demonstrated high efficacy in the treatment of Refractory/relapsed b-cell non-Hodgkin lymphomas. However, a non-negligible percentage of patients do not respond to therapy and/or develop significant treatment toxicity.
Conditions
Sponsors & Collaborators
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-30
- Primary Completion
- 2028-12-31
- Completion
- 2028-12-31
Countries
- Italy
Study Locations
More Related Trials
-
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
NCT07098364 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma
NCT06478381 ·Status: RECRUITING ·Phase: PHASE1
-
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
NCT01369784 ·Status: COMPLETED
-
Refractory Diffuse Large B-cell Lymphoma
NCT03664336 ·Status: COMPLETED
-
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
NCT00556127 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
NCT03372837 ·Status: COMPLETED ·Phase: PHASE3
-
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
NCT01321541 ·Status: COMPLETED ·Phase: PHASE3
-
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma
NCT04419441 ·Status: UNKNOWN
-
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT01647971 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
NCT06734078 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
NCT06733987 ·Status: RECRUITING
-
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
NCT01693614 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
NCT06139406 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT03576443 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT01741792 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
NCT03824951 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
NCT05267054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068 ·Status: COMPLETED ·Phase: PHASE1
-
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT05338892 ·Status: COMPLETED
-
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
NCT06996132 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
NCT06970496 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT05798156 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2